Jasper Therapeutics Inc JSPR

Healthcare Biotechnology

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

NDAQ:JSPR - Post by User

Jasper Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Feb 05, 2024 2:30am

70 Views

Post# 35862430

When (JSPR) Moves Investors should Listen

Breaking News: $JSPR When (JSPR) Moves Investors should Listen2024-02-05 01:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...JSPR - When (JSPR) Moves Investors should Listen

<< Previous

Bullboard Posts

Next >>

Buzz on the Bullboards: TSX spotlight: Bombardier, Sonoro and PyroGenesis